SUNNYVALE, Calif., Nov. 5, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the first CyberKnife® M6™ and TomoTherapy® Systems in Chile are now installed at Fundacion Arturo Lopez Perez (FALP) Cancer Institute in Santiago, Chile. FALP is also the first hospital in Latin America to install both Accuray systems. The devices provide a noninvasive treatment option and are used worldwide for delivering precise radiation therapy while maximizing patients' quality of life during and after treatment. The radiation therapy team at FALP expects to begin treating patients in the first quarter of 2016.
For more information on the CyberKnife and TomoTherapy Systems visit http://www.accuray.com.
Government officials, including Chilean President Michelle Bachelet, will attend FALP's opening ceremony today in support of the institute's commitment to becoming an international leader in the prevention, detection and treatment of cancer. The non-profit institute is dedicated to providing the best treatment possible regardless of a person's economic status and to supporting families with socioeconomic vulnerability.
"Our mission at FALP is to provide each cancer patient with high-quality treatments tailored to his or her individual needs," said Dr. Hugo Marsiglia, radiation oncologist and medical director at FALP Cancer Institute in Santiago. "With the two systems – CyberKnife and TomoTherapy – in one location we truly have the flexibility to treat almost any patient who may benefit from radiation therapy, regardless of the size or location of the tumor(s), and proximity to critical organs."
The CyberKnife M6 Series delivers radiosurgery and stereotactic body radiation therapy (SBRT), enabling precise, high-quality dose distributions to be delivered confidently to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The system accounts for patient and tumor motion by adjusting automatically in real-time, ensuring on-target delivery of radiation. CyberKnife is the only robotic radiosurgery system available today which delivers such high precision treatments for intra- and extra-cranial disease sites throughout the body including the prostate, lung, brain, spine, liver, pancreas and kidney.
"Working with the FALP team to bring the most advanced radiation therapy solutions to the people of Chile represents our commitment to increasing access to our technology around the world," said Joshua H. Levine, president and chief executive officer of Accuray. "With the CyberKnife and TomoTherapy Systems, FALP has the ability to significantly and positively impact the way cancer is managed, and bring new hope to people who would otherwise be without options."
The TomoTherapy System is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy (IMRT). Based on a CT scanner platform, the system provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles. These unique features, combined with daily 3D image guidance, enable physicians to deliver highly accurate, individualized dose distributions which precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients. The TomoTherapy® System is capable of treating all standard radiation therapy indications including breast, prostate, lung and head and neck cancers, in addition to complex treatments such as total marrow irradiation.
About Accuray Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, market adoption of the company's products and Accuray's leadership position radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015 and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated